WeWork IPO sees 13% subscription on day 2, retail demand at 0.37xWeWork India’s ₹3,000-crore IPO saw muted demand with just 13 per cent subscription on day two. The issue, priced between ₹615 and ₹648 per share, closes on October 7 and is entirely an offer for sale, with no proceeds going to the company. Anchor investors committed ₹1,348 crore ahead of the IPO. Brokerages are cautious, citing strong brand and profitability but raising concerns over high valuations and fixed costs.Read more hereEli Lilly to ...

Indian authorities started a criminal investigation into a cough syrup maker following the death of more than a dozen children who consumed the product, reigniting the issue of poor control standards in the manufacturing of the medicine https://t.co/ZOQOOXSqxV ...

Core Points - Two Indian drugmakers, Sresan Pharmaceuticals and Kaysons Pharma, are under regulatory scrutiny due to cough syrups linked to child deaths in Madhya Pradesh and Rajasthan [1][2][3] - The central drug regulator found toxic contaminants, specifically diethylene glycol, in cough syrup samples, prompting bans on sales in several states [4][5] - A total of 11 children under the age of five have died, with the cough syrup Coldrif from Sresan Pharmaceuticals being at the center of the controversy [3][5] - The Indian health ministry reported that Coldrif contained 48.6% diethylene glycol, a harmful industrial chemical [4][5] - Following the incidents, sales of Coldrif have been banned in Madhya Pradesh, Tamil Nadu, and Kerala, and a case has been registered against Sresan Pharmaceuticals [6] - Rajasthan has suspended sales of 19 medicines from Kaysons Pharma due to adverse effects linked to its cough syrups, and health officials have faced disciplinary actions [7] Industry Insights - The issue of cough syrup safety in India is not new, with previous incidents of child deaths linked to Indian-made cough syrups reported in countries like Uzbekistan and The Gambia [2][11] - The fragmented public health regulatory system in India complicates enforcement of drug safety, as regulations are divided between central and state authorities [12] - Medical experts emphasize the need for strict dosing and caution against over-the-counter cough syrups for children under two years old due to potential serious side effects [8][9][10]

Sales for a Chinese cough syrup rose by almost a third between 2019 and 2024, reaching 635m yuan ($88m) last year. Those coughing up are not just in China, but increasingly in the West, too https://t.co/M9ILtbBKum ...